ColBar LifeScience announced today that it launched Evolence, a wholly new facial filler, in Europe during November 2004. The company has received a CE Mark for marketing Evolence in Europe and has held launch events to introduce and demonstrate the product to doctors and medical practitioners in Spain, Italy, France, Germany, Belgium and the UK.
Evolence is a natural collagen product with excellent safety profile that maintains its aesthetic corrective effects for a period of at least 12 months. It is an opaque gel comprising collagen at a concentration of 35 mg/ml, supplied in a one ml. pre-filled syringe that can be stored at room temperature.
ColBar stated that the evidence for the safety and efficacy was proven in series of pre-clinical studies and a clinical trial in leading medical centre in Europe. Additional studies are currently being held in Europe.
ColBar’s patented Glymatrix technology uses natural sugar agents to mimic the process used by glucose for cross-linking collagen molecules.
ColBar CEO Itay Itzhaky stated, "After seven years of R&D, ColBar has succeeded in developing a durable product that is absorbed naturally in the body and is safe for use."
In the past two years, ColBar has invested over $5 million in building the company's plant in Rehovot Biotech Industrial Zone with state-of-the-art R&D labs and two production lines for both solid and injectable products.
In addition, ColBar invested in the branding process of Evolence with leading branding consultancy firm Wolff Olins, signed distribution deals with leading European firms, expanded its clinical trials capabilities and received product endorsement from leading doctors in Europe.
The company’s first product to market, Ossix, was launched three years ago and is used to help in generating the extra bone mass required in certain dental implant procedures (guided bone regeneration). Ossix has received FDA clearance and a CE Mark in Europe , and is marketed worldwide by Implant Innovations Inc. (3i), a global leader in dental implants.
ColBar was founded in 1995 and currently has 60 employees based in its headquarters in Herzliya and its plant in Rehovot. ColBar is backed financially by Biomedical Investments, Genesis Partners, Pitango Venture Capital and Evergreen Venture Partners. The company recently completed a fourth round of financing and has raised a total of $31 million since its establishment.
Published by Globes [online], Israel business news - www.globes.co.il - on Thursday, March 10, 2005